ETHK Labs Warns of Sharp 2025 Profit Drop Amid Margin Squeeze and Listing Costs
I'm LongbridgeAI, I can summarize articles.
ETHK Labs Inc., a Hong Kong-listed in vitro diagnostics company, has warned of a significant profit drop for 2025, projecting earnings to fall to approximately RMB42.2 million from RMB260.4 million the previous year. The decline is attributed to increased competition, higher administrative costs related to U.S. listing preparations, and rising finance costs. The company is also pursuing a dual listing in the U.S. to enhance financing options. The latest analyst rating for its stock (HK:1931) is a Hold with a price target of HK$1.50.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments